|
| Treatment | Dose | Indication and reference |
|
| Corticosteroids versus placebo | 40 mg/every 3 w | Decrease the frequency of EN in women [36] |
| Colchicine versus placebo | 1–2 mg/d | Decreases the frequency of EN and effective on arthralgia [37]
Reduces the occurrence of GUs, EN, and arthritis in women and the occurrence of arthritis in men [38] |
| 1 mg/d | Decrease in overall disease activity index and significant improvement in OUs, GUs, PPLs, and EN [39] |
| Colchicine versus Colchicine + Benzathine penicillin | 1–2 mg/d; 1.2 MU/3 w | Combined treatment more effective in reducing frequency of arthritic episodes, duration and frequency of OUs and EN, and the frequency of GUs [40] |
| Colchicine versus Benzathine penicillin versus Colchicine + Benzathine penicillin | 1 mg/d; 1.2 MU/mo | Combined use of colchicine and benzathine penicillin treatment more effective than colchicine or penicillin alone [41] |
| Rebamipide versus placebo | 300 mg/d | Reduces the number of OUs and pain [42] |
| Zinc sulfate versus placebo | 300 mg/d | Significant improvement in the clinical manifestations index of mucocutaneous lesions [43] |
| Dapsone versus placebo | 100 mg/d | Effective on the number, healing time and frequency of OUs, number of GUs, and frequency of EN and PPLs. Suppresses arthritis and epididymitis [44] |
| Thalidomide versus placebo | 100–300 mg/d | Sustained remission of OUs, GUs, and PPLs [45] |
| Azathioprine versus placebo | 2,5 mg/kg/d | Reduces the occurrence of OUs, GUs, arthritis, and ocular symptoms. Prevents the development of new eye disease [46] |
| Cyclophosphamide + Corticosteroids versus Corticosteroids | 1 g/m2/mo | Combined treatment of CCP and corticosteroids more effective in eye disease than corticosteroids alone [47] |
| Cyclosporin A versus Colchicine | 10 mg/kg/d | CyA more effective on the severity and frequency of OUs, GUs, and PPLs. Superior to colchicine in decreasing the frequency and severity of ocular attacks [48] |
| Cyclosporin A versus conventional treatments (prednisolon, chlorambucil) | 10 mg/kg/d | CsA more effective than conventional therapy in ocular disease, however, conventional therapy superior to CyA in controlling OUs, GUs, and arthritis [49] |
| Cyclosporin A versus conventional treatments (prednisolon, chlorambucil) | 10 mg/kg/d | Improvement of hearing loss in 25% of patients receiving CyA treatment [50] |
| Cyclosporin A versus Cyclophosphamide | 5 mg/kg/d | A significant improvement in VA during the first 6 months in CyA group compared with CCP [51] |
| Cyclosporin A versus conventional treatments (prednisolon, Azathioprine) | 5 mg/kg/d | CyA more effective than conventional therapy in OUs, GUs, cutaneous lesions, thrombophlebitis as well as articular and neurologic symptoms [52] |
| Interferon-α versus placebo | 6 MU/d-3 x/w | Effective on pain and healing time of OUs and frequency of GUs and PPLs. Also helpful in decreasing frequency and duration of EN, TFB, and articular symptoms [54] |
| Etanercept versus placebo | 25 mg/d-2 x/w | Reduces the occurrence of OUs, nodular skin lesions, and PPLs [64] |
| Rituximab versus cytotoxic combination therapy | 2 1000-mg courses (15-day interval) | A significant improvement in total adjusted disease activity index in rituximab group [65] |
|
